FDG-PET/CT’s ability to find a significant number of distant metastases in patients with newly diagnosed clinical stage IIB triple-negative breast cancer suggests that current guidelines from the National Comprehensive Cancer Network (NCCN) for the modality’s use may need to be revised. {read more here}